Specific immunotherapy with recombinant birch pollen allergen rBet v 1-FV is clinically efficacious-results of a phase III study

被引：0
|
作者：
Kettner, J. [1 ]
Meyer, H. [1 ]
Narkus, A. [1 ]
Cromwell, O. [1 ]
Jost, K. [1 ]
机构：
[1] Res & Dev, Allergopharma Joachim Ganzer KG, Reinbek, Germany
来源：
ALLERGY | 2007年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：33 / 33
页数：1
相关论文
共 29 条
  • [1] Specific immunotherapy with recombinant birch pollen allergen rBet v 1-FV results of 2 years of treatment (Phase II trial)
    Kettner, J.
    Meyer, H.
    Cromwell, O.
    Narkus, A.
    Jost, K.
    ALLERGY, 2007, 62 : 262 - 262
  • [2] Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1-FV in a randomized controlled trial
    Klimek, Ludger
    Bachert, Claus
    Lukat, Karl-Friedrich
    Pfaar, Oliver
    Meyer, Hanns
    Narkus, Annemie
    CLINICAL AND TRANSLATIONAL ALLERGY, 2015, 5
  • [3] Efficacy and safety of four dose regimes of a hypoallergenic recombinant birch pollen major allergen (rBet v 1-FV) in birch pollen allergic patients studied in an environmental exposure chamber
    Meyer, W.
    Narkus, A.
    Salapatek, A.
    Patel, D.
    Mussler, S.
    Haefner, D.
    ALLERGY, 2012, 67 : 89 - 89
  • [4] Effects of subcutaneous specific immunotherapy with recombinant hypoallergenic Bet v 1 folding variant (rBet v 1-FV) on asthma symptoms
    Haefner, D.
    Tribanek, M.
    Kettner, J.
    Narkus, A.
    ALLERGY, 2013, 68 : 475 - 476
  • [5] Double blind placebo-controlled allergen-specific immunotherapy with the hypoallergenic folded variant of rBet v 1-FV in birch associated soy allergy
    Treudler, R.
    Franke, A.
    Schmiedeknecht, A.
    Ballmer-Weber, B.
    Worm, M.
    Werfel, T.
    Jappe, U.
    Biedermann, T.
    Schmitt, J.
    Brehler, R.
    Kleinheinz, A.
    Kleine-Tebbe, J.
    Bruning, H.
    Rueff, F.
    Ring, J.
    Saloga, J.
    Schakel, K.
    Merk, H.
    Holzhauser, T.
    Vieths, S.
    Simon, J. C.
    ALLERGY, 2016, 71 : 56 - 57
  • [6] BASALIT trial: double-blind placebo-controlled allergen immunotherapy with rBet v 1-FV in birch-related soya allergy
    Treudler, R.
    Franke, A.
    Schmiedeknecht, A.
    Ballmer-Weber, B.
    Worm, M.
    Werfel, T.
    Jappe, U.
    Biedermann, T.
    Schmitt, J.
    Brehler, R.
    Kleinheinz, A.
    Kleine-Tebbe, J.
    Bruening, H.
    Rueff, F.
    Ring, J.
    Saloga, J.
    Schaekel, K.
    Holzhauser, T.
    Vieths, S.
    Simon, J. C.
    ALLERGY, 2017, 72 (08) : 1243 - 1253
  • [7] The recombinant hypoallergenic variant 'Bet v 1-FV' of the major birch allergen Bet v 1 is irreversibly unfolded
    Wald, M.
    Pump, L.
    Hagen, S.
    Suck, R.
    Cromwell, O.
    Nandy, A.
    ALLERGY, 2011, 66 : 141 - 141
  • [8] SKIN TESTING WITH RECOMBINANT BIRCH ALLERGENS RBET-V-1 AND RBET-V-2 - CORRELATION WITH DETECTION OF SPECIFIC ICE ANTIBODIES BY IMMUNOBLOT OF BIRCH POLLEN
    OSTER, JP
    DEVILLER, P
    PAULI, G
    DEBLAY, F
    HEISS, S
    SUZANI, M
    VALENTA, R
    KRAFT, D
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1995, 95 (01) : 305 - 305
  • [9] Genetic engineering of recombinant hypoallergenic oligomers of the major birch pollen allergen, Bet v 1: Candidates for specific immunotherapy
    Vrtala, S
    Hirtenlehner, K
    Susani, M
    Hufnagl, P
    Binder, BR
    Vangelista, L
    Pastore, A
    Sperr, WR
    Valent, P
    Ebner, C
    Kraft, D
    Valenta, R
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 1999, 118 (2-4) : 218 - 219
  • [10] Structural characterisation of a recombinant Bet v 1 allergen established as a safe and efficacious treatment for birch pollen allergy
    Nony, E.
    Le Mignon, M.
    Lemoine, P.
    Jain, K.
    Didierlaurent, A.
    Batard, T.
    Moingeon, P.
    ALLERGY, 2014, 69 : 561 - 561
123